CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Temporarily implanted nitinol device (e.g., iTind) for benign prostatic hyperplasia

This policy addresses coverage and clinical evidence for temporarily implanted nitinol devices used to treat lower urinary tract symptoms from benign prostatic hyperplasia for Medicare Advantage and Commercial products from Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyTemporarily implanted nitinol device (e.g., iTind) for benign prostatic hyperplasia

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 5, 2023

Next Review DateFeb 18, 2026

Key ActionVerify member benefits and eligibility with the provider call center before scheduling the procedure.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance

53865HCPCS not covered

5-7 daysDevice dwell time

RCT + meta-analysisEvidence base

AUASI/IPSSOutcome measure

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determination and Rationale

Coverage decision

Covered when ALL of the following are met:

Coverage stance: Medicare Advantage: the use of a temporarily implanted nitinol device (eg, iTind) for lower urinary tract symptoms due to benign prostatic hyperplasia is not covered because the evidence is insufficient to determine effects on health outcomes.

Coverage stance: Commercial Products: the use of a temporarily implanted nitinol device (eg, iTind) for lower urinary tract symptoms due to benign prostatic hyperplasia is considered not medically necessary because the evidence is insufficient to determine effects on health outcomes.

Evidence summary: Available evidence includes a meta-analysis, 1 randomized controlled trial, and 2 single-arm multicenter prospective studies. The RCT showed a greater proportion of patients achieving ≥3-point IPSS improvement at 3 months with iTind versus sham (78.6% vs 60%; p=0.029), but differences in overall IPSS, IPSS quality of life, peak urinary flow, and sexual function measures were not significant. Network meta-analysis suggested worse urologic symptom scores for iTind versus TURP at short-term follow-up. No direct comparisons with established surgical alternatives have demonstrated net health outcome benefit.

Policy concludes evidence is insufficient to demonstrate improvement in net health outcome.

The policy states that the use of a temporarily implanted nitinol device (for example, iTind) to treat lower urinary tract symptoms from benign prostatic hyperplasia is not covered for Medicare Advantage plans and is considered not medically necessary for Commercial Products because the available evidence is insufficient to determine effects on health outcomes.

Coverage and payment are governed by the member’s subscriber agreement, benefit booklet, or employer agreement and those documents supersede this policy. For member‑specific benefits or eligibility, contact the provider call center. Prior authorization is not specified by this policy; benefit coverage may vary by contract.

For Commercial Products, the temporarily implanted nitinol device (eg, iTind) is designated not medically necessary because the evidence is insufficient to demonstrate meaningful effects on health outcomes. The policy specifically lists HCPCS code 53865 as not medically necessary for Commercial members.

Services determined to be not medically necessary or non‑covered (including claims billed with HCPCS code 53865) may not be payable. Members may be held financially responsible for such services unless they were informed and provided written agreement to proceed at their own expense in advance. Providers should verify benefits and document member acknowledgment when applicable.

Billing Codes and Coverage Status

Not covered / Not medically necessary HCPCSHCPCSNot Covered

53865

Cystourethroscopy with insertion of temporary device for ischemic remodeling (ie, pressure necrosis) of bladder neck and prostate

Provider Responsibilities, Authorization, and Billing Risks

Prior Authorization

Prior authorization is not required for temporarily implanted nitinol devices. Benefits and coverage may vary by contract; confirm member-specific requirements before scheduling.

Prior authorization: Not applicable for this policy

Note

Benefit and Eligibility Verification

Contact the provider call center to verify member-specific benefits and eligibility. Coverage is governed by the subscriber agreement, Evidence of Coverage, or Benefit Booklet.

Call provider call center for member benefits and eligibility
Benefits governed by subscriber agreement/Benefit Booklet/Evidence of Coverage

Note

Treatment Sequencing

Clinical Background

Benign prostatic hyperplasia (BPH) is a common condition in older adults that can produce lower urinary tract symptoms such as increased frequency, urgency, hesitancy, nocturia, and a weak urinary stream. Temporarily implanted nitinol devices (eg, iTind) are a minimally invasive, cystoscopically placed implant intended to remodel prostatic tissue by applying circumferential force with expanding struts; the device is typically removed after approximately 5–7 days. Standard management often begins with medical therapy, with surgical options reserved for patients who do not respond to or cannot tolerate medical treatment.

Device and Outcome Definitions

Temporarily implanted nitinol device (iTind / TIND) — device description, mechanism, placement and dwell time

Device compositionNitinol implant with three double-intertwined struts configured in a tulip shape (second-generation iTind); first-generation had an extra strut and a pointed tip covered by soft plastic.

Mechanism of actionStruts gradually expand to apply circumferential force causing ischemic necrosis of the prostatic urethral mucosa, producing tissue reshaping and longitudinal channels to improve urine outflow.

Typical placementInserted into the obstructed prostatic urethra using a rigid cystoscope; distal nylon retrieval wire remains external to facilitate removal.

Dwell time (typical)Implant is typically removed after 5 to 7 days of treatment.

Removal techniqueRetrieval via the distal nylon wire using a snare to pull the device into a cystoscope sheath or an open-ended silicone catheter (20–22 Fr).

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyTemporarily implanted nitinol device (e.g., iTind) for benign prostatic hyperplasia

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 5, 2023

Next Review DateFeb 18, 2026

Key ActionVerify member benefits and eligibility with the provider call center before scheduling the procedure.

SourceLink

On This Page

Medical therapy is generally considered first-line for BPH (alpha-adrenergic blockers, 5‑alpha‑reductase inhibitors, or combination therapy). Patients who fail or cannot tolerate medical therapy may be considered for surgical options per clinical guidelines.

First-line medical therapies: α-adrenergic blockers, 5α-reductase inhibitors, combination therapy

Documentation Required

Procedure Documentation

The temporarily implanted nitinol device is typically inserted transurethrally using a rigid cystoscope and removed after approximately 5–7 days. Device retrieval is performed using the attached retrieval wire and may require a snare and either a cytoscope sheath or an open-ended silicone catheter (20–22 Fr). Document implantation and removal procedure details in the medical record.

Typical implant dwell time: removed after 5–7 days
Approach: transurethral insertion with rigid cystoscope; retrieval via nylon wire and snare into cytoscope sheath or 20–22 Fr catheter

Denial Risk

Claims Denial Risk and Patient Liability

Claims submitted with HCPCS code 53865 (Cystourethroscopy with insertion of temporary device for ischemic remodeling) are considered not covered / not medically necessary and are at risk for denial. If services are denied as not medically necessary or are non‑covered, the member may be financially responsible unless prior written agreement is obtained.

HCPCS 53865 — not covered / not medically necessary
Denial may result in patient financial liability unless prior written agreement obtained

AUASI/IPSS — patient-reported symptom score

NameAUASI (American Urological Association Symptom Index) / IPSS (International Prostate Symptom Score)

TypePatient‑reported 7‑item symptom questionnaire with an additional quality-of-life 'bother' question in the IPSS version.

Scoring rangeTotal scores range from 0 to 35.

Severity categoriesMild: ≤7; Moderate: 8–19; Severe: 20–35.

Use in policyUsed to quantify BPH symptom severity and monitor treatment effect in studies of temporarily implanted nitinol devices.

iTind — short identifier / definition

TermiTind

DefinitionTemporary implantable nitinol device used in the prostatic urethra to apply expanding struts that induce ischemic remodeling to relieve LUTS from BPH.

Evidence referencedEvaluated in randomized and single-arm studies with multiple peer-reviewed follow-ups (see referenced studies and guidelines).

Alternate nameTIND (temporary implantable nitinol device) — first/second generation distinctions noted in literature.